文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

大型多站点癌症中心提高DPYD基因分型采纳率的障碍与对策

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
PubMed 文献 · Am J Health Syst Pharm · 2023-01-01

本文描述某大型多站点癌症中心实施内部基因分型项目以检测与二氢嘧啶脱氢酶(DPD)代谢受损相关的遗传变异,并分析实施障碍与克服机制以促进检测采纳。2020年3月至2022年6月,在两个胃肠肿瘤门诊共对137例患者进行基因分型,其中13例(9.5%)为杂合变异携带者,被鉴定为DPYD中间代谢者。结论认为,通过工作流程操作化克服传统检测障碍并获得所有利益相关者参与,在多站点癌症中心实施DPYD基因分型是可行的。

要点

  • DPYD中间和慢代谢者因氟嘧啶清除减少而面临相关不良事件风险增加。
  • 实施障碍包括教育/认识不足、缺乏肿瘤专业组织推荐、检测成本、可及性和周转时间。
  • 137例基因分型中13例(9.5%)为杂合变异,鉴定为DPYD中间代谢者。

核心结论

  • 在多站点癌症中心实施DPYD基因分型是可行的,归因于工作流程操作化克服传统检测障碍以及所有利益相关者的参与。

研究设计与样本

  • 本文为某大型多站点癌症中心内部基因分型项目实施描述,包含障碍分析与克服机制。
  • 2020年3月至2022年6月,在两个胃肠肿瘤门诊共对137例患者进行基因分型。

主要发现

  • 137例基因分型患者中,13例(9.5%)为杂合变异携带者,被鉴定为DPYD中间代谢者。
  • DPYD中间和慢代谢者因特定遗传变异可出现氟嘧啶清除减少和相关不良事件风险增加。

临床怎么用

  • 基于利益相关者反馈开发内部DPYD检测和工作流程,以促进多个诊所地点的检测。
  • 未来方向包括电子病历整合(如中断性警报)、建立计费基础设施和进一步优化工作流程以提高治疗前检测率。

局限性

  • 检测尚未在美国广泛采纳,原因包括教育/认识有限、缺乏肿瘤专业组织检测推荐、检测成本、缺乏全面内部检测服务可及性和检测周转时间延长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the implementation of an in-house genotyping program to detect genetic variants linked to impaired dihydropyrimidine dehydrogenase (DPD) metabolism at a large multisite cancer center, including barriers to implementation and mechanisms to overcome barriers to facilitate test adoption. SUMMARY: Fluoropyrimidines, including fluorouracil and capecitabine, are commonly used chemotherapy agents in the treatment of solid tumors, such as gastrointestinal cancers. DPD is encoded by the DPYD gene, and individuals classified as DPYD intermediate and poor metabolizers due to certain genetic variations in DPYD can experience reduced fluoropyrimidine clearance and an increased risk of fluoropyrimidine-related adverse events. Although pharmacogenomic guidelines provide evidence-based recommendations for DPYD genotype-guided dosing, testing has not been widely adopted in the United States for numerous reasons, including limited education/awareness of clinical utility, lack of testing recommendations by oncology professional organizations, testing cost, lack of accessibility to a comprehensive in-house test and service, and prolonged test turnaround time. Based on stakeholder feedback regarding barriers to testing, we developed an in-house DPYD test and workflow to facilitate testing in multiple clinic locations at Levine Cancer Institute. Across 2 gastrointestinal oncology clinics from March 2020 through June 2022, 137 patients were genotyped, and 13 (9.5%) of those patients were heterozygous for a variant and identified as DPYD intermediate metabolizers. CONCLUSION: Implementation of DPYD genotyping at a multisite cancer center was feasible due to operationalization of workflows to overcome traditional barriers to testing and engagement from all stakeholders, including physicians, pharmacists, nurses, and laboratory personnel. Future directions to scale and sustain testing in all patients receiving a fluoropyrimidine across all Levine Cancer Institute locations include electronic medical record integration (eg, interruptive alerts), establishment of a billing infrastructure, and further refinement of workflows to improve the rate of pretreatment testing.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Morris SA, Moore DC, Musselwhite LW, et al. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center. Am J Health Syst Pharm. 2023. PMID: 37235983. doi:10.1093/ajhp/zxad117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。